MOGAD comes of age with new criteria

Clinical interest in myelin-oligodendrocyte glycoprotein (MOG) autoantibodies has increased remarkably in the past decade, and the term MOG antibody-associated disease (MOGAD) has been coined to include several clinical and radiological syndromes, most of which are demyelinating, that occur in individuals with these antibodies.1–3 The associated symptoms have a monophasic or relapsing course that can be mistaken for multiple sclerosis or neuromyelitis optica spectrum disorders associated with aquaporin-4 antibodies.